A phase II dose-ranging study of mirabegron in patients with overactive bladder

被引：0
|
作者：
Christopher R. Chapple
Vladimir Dvorak
Pjotr Radziszewski
Philip Van Kerrebroeck
Jean Jacques Wyndaele
Brigitte Bosman
Peter Boerrigter
Ted Drogendijk
Arwin Ridder
Ingrid Van Der Putten-Slob
Osamu Yamaguchi
机构：
[1] Sheffield Teaching Hospitals,Department of Urology, Royal Hallamshire Hospital
[2] Centrum ambulantní gynekologie a primární péce,Department of Urology
[3] Medical University Warsaw,Department Urology
[4] Maastricht University Medical Center,Department of Urology
[5] Antwerp University and Antwerp University Hospital,Division of Bioengineering and LUTD Research, School of Engineering
[6] Astellas Pharma Europe BV,undefined
[7] Nihon University,undefined
来源：
International Urogynecology Journal | 2013年 / 24卷
关键词：
β; -adrenoceptor agonist; Mirabegron; Overactive; Urinary bladder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1447 / 1458
页数：11
相关论文
共 50 条
  • [1] A phase II dose-ranging study of mirabegron in patients with overactive bladder
    Chapple, Christopher R.
    Dvorak, Vladimir
    Radziszewski, Pjotr
    Van Kerrebroeck, Philip
    Wyndaele, Jean Jacques
    Bosman, Brigitte
    Boerrigter, Peter
    Drogendijk, Ted
    Ridder, Arwin
    Van der Putten-Slob, Ingrid
    Yamaguchi, Osamu
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2013, 24 (09) : 1447 - 1458
  • [2] Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
    Abrams, Paul
    Kelleher, Con
    Staskin, David
    Rechberger, Tomasz
    Kay, Richard
    Martina, Reynaldo
    Newgreen, Donald
    Paireddy, Asha
    van Maanen, Rob
    Ridder, Arwin
    EUROPEAN UROLOGY, 2015, 67 (03) : 577 - 588
  • [3] Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)
    P. Abrams
    C. Kelleher
    D. Staskin
    R. Kay
    A. Martan
    I. Mincik
    D. Newgreen
    A. Ridder
    A. Paireddy
    R. van Maanen
    World Journal of Urology, 2017, 35 : 827 - 838
  • [4] Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)
    Abrams, P.
    Kelleher, C.
    Staskin, D.
    Kay, R.
    Martan, A.
    Mincik, I.
    Newgreen, D.
    Ridder, A.
    Paireddy, A.
    van Maanen, R.
    WORLD JOURNAL OF UROLOGY, 2017, 35 (05) : 827 - 838
  • [5] Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder
    Blais, Anne-Sophie
    Nadeau, Genevieve
    Moore, Katherine
    Genois, Lucie
    Bolduc, Stephane
    EUROPEAN UROLOGY, 2016, 70 (01) : 9 - 13
  • [6] Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder
    Nitti, Victor W.
    Auerbach, Stephen
    Martin, Nancy
    Calhoun, Alaina
    Lee, Misun
    Herschorn, Sender
    JOURNAL OF UROLOGY, 2013, 189 (04) : 1388 - 1395
  • [7] Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
    Christopher R. Chapple
    Victor W. Nitti
    Vik Khullar
    Jean Jacques Wyndaele
    Sender Herschorn
    Philip van Kerrebroeck
    Mary Beth Blauwet
    Emad Siddiqui
    World Journal of Urology, 2014, 32 : 1565 - 1572
  • [8] A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder
    Phiri, Kelesitse
    Hallas, Jesper
    Linder, Marie
    Margulis, Andrea
    Suehs, Brandon
    Arana, Alejandro
    Bahmanyar, Shahram
    Hoffman, Veena
    Enger, Cheryl
    Horter, Libby
    Odsbu, Ingvild
    Olesen, Morten
    Perez-Gutthann, Susana
    Kristiansen, Nina Sahlertz
    Appenteng, Kwame
    de Vogel, Stefan
    Seeger, John
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (05) : 867 - 877
  • [9] Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
    Chapple, Christopher R.
    Nitti, Victor W.
    Khullar, Vik
    Wyndaele, Jean Jacques
    Herschorn, Sender
    van Kerrebroeck, Philip
    Blauwet, Mary Beth
    Siddiqui, Emad
    WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1565 - 1572
  • [10] Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study)
    Cho, Sung Yong
    Jeong, Seong Jin
    Lee, Sangchul
    Kim, Janghwan
    Lee, Seong Ho
    Choo, Min Soo
    Oh, Seung-June
    NEUROUROLOGY AND URODYNAMICS, 2021, 40 (01) : 286 - 294
12345